Intramyocardial, Autologous CD34+Cell Therapy for Refractory Angina

被引:376
|
作者
Losordo, Douglas W. [1 ]
Henry, Timothy D. [2 ]
Davidson, Charles
Lee, Joon Sup [3 ]
Costa, Marco A. [4 ]
Bass, Theodore [5 ]
Mendelsohn, Farrell [6 ]
Fortuin, F. David [7 ]
Pepine, Carl J. [8 ]
Traverse, Jay H. [2 ]
Amrani, David [9 ]
Ewenstein, Bruce M. [9 ]
Riedel, Norbert [9 ]
Story, Kenneth [9 ]
Barker, Kerry [9 ]
Povsic, Thomas J. [10 ]
Harrington, Robert A. [10 ]
Schatz, Richard A. [11 ]
机构
[1] Northwestern Univ, NW Mem Hosp, Program Cardiovasc Regenerat Med, Div Cardiol, Chicago, IL 60611 USA
[2] Abbott NW Hosp, Minneapolis Heart Inst Fdn, Minneapolis, MN 55407 USA
[3] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA
[4] Case Western Reserve Univ, Univ Hosp Case Med Ctr, Cleveland, OH 44106 USA
[5] Shands Jacksonville Med Ctr, Jacksonville, FL USA
[6] Ctr Therapeut Angiogenesis, Birmingham, AL USA
[7] Mayo Clin, Scottsdale, AZ USA
[8] Univ Florida, Gainesville, FL USA
[9] Baxter Healthcare Corp, Deerfield, IL 60015 USA
[10] Duke Univ, Duke Clin Res Inst, Durham, NC USA
[11] Scripps Green Hosp, La Jolla, CA USA
关键词
angiogenesis; endothelial progenitor cells (EPC) myocardial ischemia; myocardial regeneration; stem cells; PERCUTANEOUS CORONARY INTERVENTION; MYOCARDIAL-INFARCTION; UNIVERSAL DEFINITION; CELL TRANSPLANTATION; RANDOMIZED-TRIAL; RESEARCH ISSUES; ARTERY-DISEASE; HEART-DISEASE; DOUBLE-BLIND; ANGIOGENESIS;
D O I
10.1161/CIRCRESAHA.111.245993
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Rationale: A growing number of patients with coronary disease have refractory angina. Preclinical and early-phase clinical data suggest that intramyocardial injection of autologous CD34+ cells can improve myocardial perfusion and function. Objective: Evaluate the safety and bioactivity of intramyocardial injections of autologous CD34+ cells in patients with refractory angina who have exhausted all other treatment options. Methods and Results: In this prospective, double-blind, randomized, phase II study (ClinicalTrials.gov identifier: NCT00300053), 167 patients with refractory angina received 1 of 2 doses (1X10(5) or 5X10(5) cells/kg) of mobilized autologous CD34+ cells or an equal volume of diluent (placebo). Treatment was distributed into 10 sites of ischemic, viable myocardium with a NOGA mapping injection catheter. The primary outcome measure was weekly angina frequency 6 months after treatment. Weekly angina frequency was significantly lower in the low-dose group than in placebo-treated patients at both 6 months (6.8 +/- 1.1 versus 10.9 +/- 1.2, P=0.020) and 12 months (6.3 +/- 1.2 versus 11.0 +/- 1.2, P=0.035); measurements in the high-dose group were also lower, but not significantly. Similarly, improvement in exercise tolerance was significantly greater in low-dose patients than in placebo-treated patients (6 months: 139 +/- 151 versus 69 +/- 122 seconds, P=0.014; 12 months: 140 +/- 171 versus 58 +/- 146 seconds, P=0.017) and greater, but not significantly, in the high-dose group. During cell mobilization and collection, 4.6% of patients had cardiac enzyme elevations consistent with non-ST segment elevation myocardial infarction. Mortality at 12 months was 5.4% in the placebo-treatment group with no deaths among cell-treated patients. Conclusions: Patients with refractory angina who received intramyocardial injections of autologous CD34+ cells (10(5) cells/kg) experienced significant improvements in angina frequency and exercise tolerance. The cell-mobilization and -collection procedures were associated with cardiac enzyme elevations, which will be addressed in future studies. (Circ Res. 2011;109:428-436.)
引用
收藏
页码:428 / 436
页数:9
相关论文
共 50 条
  • [1] INTRAMYOCARDIAL AUTOLOGOUS CD34+CELL THERAPY FOR REFRACTORY ANGINA: A META-ANALYSIS
    Velagapudi, Poonam
    Turagam, Mohit
    Kolte, Dhaval
    Khera, Sahil
    Aronow, Herbert
    Leopold, Jane
    Abbott, J.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 69 (11) : 1064 - 1064
  • [2] Intramyocardial Autologous CD34+Cell Therapy Reduces Mortality and Improves Exercise Capacity in Patients with Refractory Angina
    Povsic, Thomas
    Henry, Timothy
    Jolicoeur, Marc
    Traverse, Jay
    Schatz, Richard
    Hunt, Andrea
    Losordo, Douglas
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2016, 68 (18) : B332 - B333
  • [3] Intramyocardial autologous CD34+ cell therapy for refractory angina: A meta-analysis of randomized controlled trials
    Velagapudi, Poonam
    Turagam, Mohit
    Kolte, Dhaval
    Khera, Sahil
    Hyder, Omar
    Gordon, Paul
    Aronow, Herbert D.
    Leopold, Jane
    Abbott, J. Dawn
    CARDIOVASCULAR REVASCULARIZATION MEDICINE, 2019, 20 (03) : 215 - 219
  • [4] Autologous CD34+Cell Therapy for Refractory Angina: 12 Month Results of the Phase II ACT34-CMI Study
    Losordo, Douglas W.
    Henry, Tim
    Schatz, Richard A.
    Lee, Joon Sup
    Costa, Marco
    Bass, Theodore
    Schaer, Gary
    Niederman, Alan
    Mendelsohn, Farrell
    Davidson, Charles
    Waksman, Ron
    Soukas, Peter A.
    Simon, Daniel
    Chronos, Nicolas
    Fortuin, F. David
    Huang, Paul P.
    Weintraub, Neal
    Yeung, Alan
    Rosenfield, Kenneth
    Wong, S. Chiu
    Taussig, Andrew
    Rava, Amish N.
    Sherman, Warren
    Kereiakes, Dean
    Strumpf, Robert K.
    Port, Steven
    Pieper, Karen
    Adams, Peter X.
    Harrington, Robert
    CIRCULATION, 2009, 120 (18) : S1132 - S1132
  • [5] The RENEW Trial Efficacy and Safety of Intramyocardial Autologous CD34+ cell Administration in Patients With Refractory Angina
    Povsic, Thomas J.
    Henry, Timothy D.
    Traverse, Jay H.
    Fortuin, F. David
    Schaer, Gary L.
    Kereiakes, Dean J.
    Schatz, Richard A.
    Zeiher, Andreas M.
    White, Christopher J.
    Stewart, Duncan J.
    Jolicoeur, E. Marc
    Bass, Theodore
    Henderson, David A.
    Dignacco, Patricia
    Gu, Ziangoiong
    Al-Khalidi, Hussein R.
    Junge, Candice
    Nada, Adel
    Hunt, Andrea S.
    Losordo, Douglas W.
    JACC-CARDIOVASCULAR INTERVENTIONS, 2016, 9 (15) : 1576 - 1585
  • [6] Autologous CD34+Cell Therapy for Ischemic Tissue Repair
    Sietsema, William K.
    Kawamoto, Atsuhiko
    Takagi, Hiroshi
    Losordo, Douglas W.
    CIRCULATION JOURNAL, 2019, 83 (07) : 1422 - 1430
  • [7] Cd34+Cell Therapy Significantly Reduces Adverse Cardiacevents and Healthcare Expenditures in Patients With Refractory Angina.
    Johnson, Grace L.
    Henry, Timothy D.
    Povsic, Thomas J.
    Losordo, Doug W.
    Stanberry, Larissa, I
    Traverse, Jay H.
    CIRCULATION, 2018, 138
  • [8] Randomized, Double-Blind, Placebo-Controlled Trial of Autologous CD34+Cell Therapy for Refractory Angina: 2-Year Safety Analysis
    Losordo, Douglas W.
    Henry, Timothy D.
    Schatz, Richard A.
    Lee, Joon Sup
    Costa, Marco
    Bass, Theodore
    Schaer, Gary L.
    Mendelsohn, Farrell
    Davidson, Charles
    Waksman, Ron
    Soukas, Peter A.
    Simon, Daniel
    Chronos, Nicolas
    Fortuin, F. David
    Huang, Paul P.
    Weintraub, Neal
    Yeung, Alan
    Rosenfield, Kenneth
    Wong, S. Chiu
    Taussig, Andrew
    Raval, Amish N.
    Sherman, Warren
    Kereiakes, Dean
    Strumpf, Robert K.
    Port, Steven
    Pieper, Karen
    Ewenstein, Bruce
    Story, Kenneth O.
    Barker, Kerry B.
    Harrington, Robert A.
    CIRCULATION, 2010, 122 (21)
  • [9] CHANGES IN NON-INVASIVE CORONARY FLOW RESERVE BY PET AFTER INTRAMYOCARDIAL, AUTOLOGOUS CD34+CELL THERAPY FOR ISCHEMIC CARDIOMYOPATHY
    Johnson, Nils P.
    Gould, K. Lance
    Losordo, Douglas W.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2011, 57 (14) : E238 - E238
  • [10] Enrichment of autologous CD34+cell products for intramyocardial application by means of CD34-positive immunomagnetic isolation in patients with dilated cardiomyopathy
    Malicev, E.
    Cukjati, M.
    Vrtovec, B.
    Krasna, M.
    Pavlovcic, P.
    Stanisc, S.
    Milojkovic, A.
    Malicev, P.
    Rozman, P.
    BONE MARROW TRANSPLANTATION, 2013, 48 : S195 - S196